相关实验视频

Updated: Jul 17, 2025

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

显著的生理特征和改变的葡萄糖信号在GHGH淘汰赛小鼠:对长寿的影响

A Tate Lasher¹, Liou Y Sun¹

¹Department of Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

|September 5, 2023

概括

缺乏生长激素释放激素 (GHRH) 的小鼠对葡萄糖的反应发生了变化,葡萄糖的产生减少,但能量消耗增加,这表明葡萄糖信号在它们延长寿命中的作用.

科学领域:

内分泌学在内分泌学.
代谢过程中的代谢.
长寿研究研究长寿研究

背景情况:

缺乏生长激素释放激素 (GHRH) 的小鼠表现出延长寿命,改变新陈代谢,增强胰岛素敏感性.
这些小鼠对禁食表现出独特的反应,促使人们对葡萄糖的作用进行调查.

研究的目的:

为了研究急性葡萄糖激素挑战对雌性GHGH淘汰小鼠的影响.
了解葡萄糖信号对这些长寿小鼠葡萄糖生产,能量消耗和代谢表型的影响.

主要方法:

向雌性GHRH淘汰赛小鼠进行了急性葡萄糖激素挑战.
分析了葡萄糖的生产,葡萄糖生成和能量消耗.
检查了胰腺岛架构和肝脏葡萄糖素信号通路,包括葡萄糖素受体表达和CREB酸化.

主要成果:

GHRH淘汰赛小鼠显示葡萄糖产量减少,可能是由于抑制的葡萄糖生成.
尽管葡萄糖产量减少,但这些小鼠的能量消耗增加.
在胰腺小岛结构中观察到变化,β细胞较少,肝脏葡萄糖受体表达和pCREB的减少.

结论:

葡萄糖激素信号的变化可能导致独特的代谢表型和延长GHRH淘汰小鼠的寿命.
对葡萄糖信号通路的进一步研究可以为哺乳动物寿命调节提供新的见解.

关键词:

延长了使用寿命.葡萄糖是一种葡萄糖.增长激素增长激素的使用方法胰岛素敏感性胰岛素敏感性

更多相关视频

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

相关概念视频

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...